Progression of chronic obstructive pulmonary disease: impact of inflammation, comorbidities and therapeutic intervention

References

• Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2007. Available at: www.goldcopd.com [Last accessed 18 February 2009]
   Google Scholar
• World Health Organization (WHO). Chronic Obstructive Pulmonary Disease. 2007. Available at: www.who.int/respiratory/copd/ [Last accessed 18 February 2009]
   Google Scholar
• Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study. Lancet 1997;349:1498-504
   PubMed Web of Science ®Google Scholar
• Halbert RJ, Natoli JL, Gano A, et al. Global burden of COPD: systematic review and meta-analysis. Eur Respir J 2006;28:523-32
   PubMed Web of Science ®Google Scholar
• Halpin DM, Miravitlles M. Chronic obstructive pulmonary disease: the disease and its burden to society. Proc Am Thoracic Soc 2006;3:619-23
   PubMedGoogle Scholar
• Miravitlles M, Murio C, Guerrero T et al, on behalf of the DAFNE Study Group. Costs of chronic bronchitis and COPD: a 1-year follow-up study. Chest 2003;123:784-91
   PubMed Web of Science ®Google Scholar
• Wouters EF. Economic analysis of the Confronting COPD Survey: an overview of results. Respir Med 2003;97 (Suppl. C):S3-14
   PubMed Web of Science ®Google Scholar
• Andersson F, Borg S, Jansson SA, et al. The costs of exacerbations in chronic obstructive pulmonary disease (COPD). Respir Med 2002;96:700-8
   PubMed Web of Science ®Google Scholar
• Halpern MT, Polzin J, Higashi MK, et al. The workplace impact of acute exacerbations of chronic bronchitis (AECB): a literature review. COPD 2004;1:249-54
   PubMedGoogle Scholar
• Seamark DA, Blake SD, Seamark CJ, et al. Living with severe chronic obstructive pulmonary disease (COPD): perceptions of patients and their carers. An interpretative phenomenological analysis. Palliat Med 2004;18:619-25
   PubMed Web of Science ®Google Scholar
• Rennard S, Decramer M, Calverley PM, et al. Impact of COPD in North America and Europe in 2000: subjects’ perspective of Confronting COPD International Survey. Eur Respir J 2002;20:799-805
   PubMed Web of Science ®Google Scholar
• Naberan K, De la Roza C, Lamban M, et al. Use of spirometry in the diagnosis and treatment of chronic obstructive pulmonary disease in primary care. Arch Bronconeumol 2006;42:638-44
   PubMed Web of Science ®Google Scholar
• Freeman D, Nordyke RJ, Isonaka S, et al. Questions for COPD diagnostic screening in a primary care setting. Respir Med 2005;99:1311-18
   PubMed Web of Science ®Google Scholar
• Decramer M, Bartsch P, Pauwels R, et al. Management of COPD according to guidelines. A national survey among Belgian physicians. Monaldi Arch Chest Dis 2003;59:62-80
   PubMedGoogle Scholar
• Altose MD. Approaches to slowing the progression of COPD. Curr Opin Pulm Med 2003;9:125-30
   PubMed Web of Science ®Google Scholar
• Agusti AG. COPD, a multicomponent disease: implications for management. Respir Med 2005;99:670-82
   PubMed Web of Science ®Google Scholar
• Agusti AG, Noguera A, Sauleda J, et al. Systemic effects of chronic obstructive pulmonary disease. Eur Respir J 2003;21:347-60
   PubMed Web of Science ®Google Scholar
• Gan WQ, Man SFP, Senthilselvan A, et al. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and meta-analysis. Thorax 2004;59:574-80
   PubMed Web of Science ®Google Scholar
• Sin DD, Anthonisen NR, Soriano JB, et al. Mortality in COPD: role of comorbidities. Eur Respir J 2006;28:1245-57
   PubMed Web of Science ®Google Scholar
• Sevenoaks MJ, Stockley RA. Chronic obstructive pulmonary disease, inflammation and co-morbidity – a common inflammatory phenotype? Respir Res 2006;7:70
   PubMed Web of Science ®Google Scholar
• Wouters EF, Creutzberg EC, Schols AM. Systemic effects in COPD. Chest 2002;121:127S-30S
   PubMed Web of Science ®Google Scholar
• Wagena EJ, Arrindell WA, Wouters EF, et al. Are patients with COPD psychologically distressed? Eur Respir J 2005;26:242-8
   PubMed Web of Science ®Google Scholar
• Wouters EF. Local and systemic inflammation in chronic obstructive pulmonary disease. Proc Am Thoracic Soc 2005;2:26-33
   PubMedGoogle Scholar
• Barnes PJ. Mediators of chronic obstructive pulmonary disease. Pharmacol Rev 2004;56:515-48
   PubMed Web of Science ®Google Scholar
• Jeffery PK. Remodelling and inflammation of bronchia in asthma and chronic obstructive pulmonary disease. Proc Am Thoracic Soc 2004;1:176-83
   PubMedGoogle Scholar
• Barnes PJ. Alveolar macrophages in chronic obstructive pulmonary disease (COPD). Cell Mol Biol 2004;50:Online Pub:OL627-37
   Web of Science ®Google Scholar
• Barnes PJ. Alveolar macrophages as orchestrators of COPD. COPD 2004;1:59-70
   PubMedGoogle Scholar
• Hogg JC. Pathophysiology of airflow limitation in chronic obstructive pulmonary disease. Lancet 2004;364:709-21
   PubMed Web of Science ®Google Scholar
• Hogg JC, Chu F, Utokaparch S, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004;350:2645-53
   PubMed Web of Science ®Google Scholar
• Stockley RA. Neutrophils and the pathogenesis of COPD. Chest 2002;121:151S-5S
   PubMed Web of Science ®Google Scholar
• Mannino DM, Ford ES, Redd SC. Obstructive and restrictive lung disease and markers of inflammation: data from the Third National Health and Nutrition Examination. Am J Med 2003;114:758-62
   PubMed Web of Science ®Google Scholar
• Wedzicha JA, Seemungal TA, MacCallum PK, et al. Acute exacerbations of COPD are accompanied by elevations of plasma fibrinogen and serum IL-6 levels. Thromb Haemost 2000;84:210-5
   PubMed Web of Science ®Google Scholar
• O’Donnell R, Breen D, Wilson S, et al. Inflammatory cells in the airways in COPD. Thorax 2006;61:448-54
   PubMed Web of Science ®Google Scholar
• Dal Negro RW, Micheletto C, Tognella S, et al. A two-stage logistic model based on the measurement of pro-inflammatory cytokines in bronchial secretions for assessing bacterial, viral, and non-infectious origin of COPD exacerbations. COPD 2005;2:7-16
   PubMedGoogle Scholar
• Yanbaeva DG, Dentener MA, Creutzberg EC, et al. Systemic effects of smoking. Chest 2007;131:1557-66
   PubMed Web of Science ®Google Scholar
• Stockley RA, Burnett D. Alpha,-antitrypsin and leukocyte elastase in infected and noninfected sputum. Am Rev Respir Dis 1979;120:1081-6
   PubMed Web of Science ®Google Scholar
• Hill AT, Campbell EJ, Bayley DL, et al. Evidence for excessive bronchial inflammation during an acute exacerbation of chronic obstructive pulmonary disease in patients with alpha(1)-antitrypsin deficiency (PiZ). Am J Respir Crit Care Med 1999;160:1968-75
   PubMed Web of Science ®Google Scholar
• Crooks SW, Bayley DL, Hill SL, et al. Bronchial inflammation in acute bacterial exacerbations of chronic bronchitis: the role of leukotriene B4. Eur Respir J 2000;15:274-80
   PubMed Web of Science ®Google Scholar
• Stockley RA, Burnett D. Alpha 1-antichymotrypsin in infected and noninfected sputum. Am Rev Respir Dis 1980;122:81-8
   PubMed Web of Science ®Google Scholar
• Stockley RA, O’Brien C, Pye A, et al. Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD. Chest 2000;117:1638-45
   PubMed Web of Science ®Google Scholar
• Gompertz S, O’Brien C, Bayley DL, et al. Changes in bronchial inflammation during acute exacerbations of chronic bronchitis. Eur Respir J 2001;17:1112-19
   PubMed Web of Science ®Google Scholar
• Hurst JR, Donaldson GC, Perera WR, et al. Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006;174:867-74
   PubMed Web of Science ®Google Scholar
• Groenewegen KH, Postma DS, Hop WC, et al. Increased systemic inflammation is a risk factor for COPD exacerbations. Chest 2008;133:350-7
   PubMed Web of Science ®Google Scholar
• Oudijk EJ, Lammers JW, Koenderman L. Systemic inflammation in chronic obstructive pulmonary disease. Eur Respir J Suppl 2003;46:5s-13s
   PubMedGoogle Scholar
• Aldonyte R, Eriksson S, Piitulainen E, et al. Analysis of systemic biomarkers in COPD patients. COPD 2004;1:155-64
   PubMedGoogle Scholar
• Hersh CP, Demeo DL, Lazarus R, et al. Genetic association analysis of functional impairment in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006;173:977-84
   PubMed Web of Science ®Google Scholar
• Hersh CP, Miller DT, Kwiatkowski DJ, et al. Genetic determinants of C-reactive protein in COPD. Eur Respir J 2006;28:1156-62
   PubMed Web of Science ®Google Scholar
• Yanbaeva DG, Dentener MA, Creutzberg EC, et al. Systemic inflammation in COPD: is genetic susceptibility a key factor? COPD 2006;3:51-61
   PubMedGoogle Scholar
• Rennard SI. Chronic obstructive pulmonary disease: linking outcomes and pathobiology of disease modification. Proc Am Thoracic Soc 2006;3:276-80
   PubMedGoogle Scholar
• Donaldson GC, et al. Airway and systemic inflammation and decline in lung function in patients with COPD. Chest 2005;128:1995-2004
   PubMed Web of Science ®Google Scholar
• Man SF, et al. C-reactive protein and mortality in mild to moderate chronic obstructive pulmonary disease. Thorax 2006;61:849-53
   PubMed Web of Science ®Google Scholar
• Parr DG, et al. Inflammation in sputum relates to progression of disease in subjects with COPD: a prospective descriptive study. Respir Res 2006;7:136
   PubMed Web of Science ®Google Scholar
• Wilkinson TM, et al. Respiratory syncytial virus, airway inflammation, and FEV1 decline in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006;173:871-6
   PubMed Web of Science ®Google Scholar
• Franciosi LG, et al. Markers of disease severity in chronic obstructive pulmonary disease. Pulm Pharmacol Ther 2006;19:189-99
   PubMed Web of Science ®Google Scholar
• Broekhuizen R, et al. Raised CRP levels mark metabolic and functional impairment in advanced COPD. Thorax 2006;61:17-22
   PubMed Web of Science ®Google Scholar
• Bhowmik A, et al. Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations. Thorax 2000;55:114-20
   PubMed Web of Science ®Google Scholar
• Hurst JR, et al. Systemic and upper and lower airway inflammation at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006;173:71-8
   PubMed Web of Science ®Google Scholar
• Papi A, et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am J Respir Crit Care Med 2006;173:1114-21
   PubMed Web of Science ®Google Scholar
• Tumkaya M, et al. Relationship between airway colonization, inflammation and exacerbation frequency in COPD. Respir Med 2007;101:729-37
   PubMed Web of Science ®Google Scholar
• Snoeck-Stroband JB, et al. Airway inflammation contributes to health status in COPD: a cross-sectional study. Respir Res 2006;7:140-7
   PubMed Web of Science ®Google Scholar
• Van Helvoort HA, et al. Exercise-induced systemic effects in muscle-wasted patients with COPD. Med Sci Sports Exerc 2006;38:1543-52
   PubMed Web of Science ®Google Scholar
• Pinto-Plata VM, et al. C-reactive protein in patients with COPD, control smokers and non-smokers. Thorax 2006;61:23-8
   PubMed Web of Science ®Google Scholar
• Yende S, et al. Inflammatory markers are associated with ventilatory limitation and muscle dysfunction in obstructive lung disease in well functioning elderly subjects. Thorax 2006;61:10-6
   PubMed Web of Science ®Google Scholar
• Panina P, Mariani M, D’Ambrosio D. Chemokine receptors in chronic obstructive pulmonary disease (COPD). Curr Drug Targets 2006;7:669-74
   PubMed Web of Science ®Google Scholar
• Hill AT, Campbell EJ, Hill SL, et al. Association between airway bacterial load and markers of airway inflammation in patients with stable chronic bronchitis. Am J Med 2000;109:288-95
   PubMed Web of Science ®Google Scholar
• Dahl M, Vestbo J, Lange P, et al. C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007;175:250-5
   PubMed Web of Science ®Google Scholar
• Wagner PD. Skeletal muscles in chronic obstructive pulmonary disease: deconditioning, or myopathy? Respirology 2006;11:681-6
   PubMed Web of Science ®Google Scholar
• Acharyya S, Ladner KJ, Nelsen LL, et al. Cancer cachexia is regulated by selective targeting of skeletal muscle gene products. J Clin Invest 2004;114:370-8
   PubMed Web of Science ®Google Scholar
• Chamberlain JS. Cachexia in cancer – zeroing in on myosin. N Engl J Med 2004;351:2124-5
   PubMed Web of Science ®Google Scholar
• Debigare R, Cote CH, Maltais F. Peripheral muscle wasting in chronic obstructive pulmonary disease. Clinical relevance and mechanisms. Am J Respir Crit Care Med 2001;164:1712-17
   PubMed Web of Science ®Google Scholar
• Sandri M, Sandri C, Gilbert A, et al. Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell 2004;117:399-412
   PubMed Web of Science ®Google Scholar
• Vestbo J, Anderson W, Coxson HO, et al. Evaluation of COPD longitudinally to identify predictive surrogate end-points (ECLIPSE). Eur Respir J 2008;31:869-73
   PubMed Web of Science ®Google Scholar
• Fabbri LM, Luppi F, Beghé B, et al. Complex chronic comorbidities of COPD. Eur Respir J 2008;31:204-12
   PubMed Web of Science ®Google Scholar
• Agusti A. Systemic effects of chronic obstructive pulmonary disease: what we know and what we don’t know (but should). Proc Am Thorac Soc 2007;4:522-5
   PubMedGoogle Scholar
• Hansell AL, Walk JA, Soriano JB. What do chronic obstructive pulmonary disease patients die from? A multiple cause coding analysis. Eur Respir J 2003;22:809-14
   PubMed Web of Science ®Google Scholar
• Calverley PMA, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356:775-89
   PubMed Web of Science ®Google Scholar
• McGarvey LP, John M, Anderson JA, et al. Ascertainment of cause-specific mortality in COPD – Operations of the TORCH Clinical Endpoint Committee. Thorax 2007;62:411-15
   PubMed Web of Science ®Google Scholar
• Wood AM, Stockley RA. Unifying the genetics, co-morbidities and management of COPD. Ther Adv Respir Dis 2008;2:113-17
   PubMedGoogle Scholar
• Joppa P, Petrasova D, Stancak B, et al. Systemic inflammation in patients with COPD and pulmonary hypertension. Chest 2006;130:326-33
   PubMed Web of Science ®Google Scholar
• Di Francia M, Barbier D, Mege JL, et al. Tumor necrosis factor-alpha levels and weight loss in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1994;150:1453-5
   PubMed Web of Science ®Google Scholar
• Ridker PM, Cannon CP, Morrow D, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005;352:20-8
   PubMed Web of Science ®Google Scholar
• Albert MA, Danielson E, Rafai N, et al. Effect of statin therapy on C-reactive protein levels: the Pravastatin Inflammation/CRP Evaluation (PRINCE): a randomized trial and cohort study. JAMA 2001;286:64-70
   PubMed Web of Science ®Google Scholar
• Stoll LL, McCormick ML, Denning GM, et al. Antioxidant effects of statins. Drugs Today (Barc) 2004;40:975-90
   PubMed Web of Science ®Google Scholar
• Søyseth V, Brekke PH, Smith P, et al. Statin use is associated with reduced mortality in COPD. Eur Respir J 2007;29:279-83
   PubMed Web of Science ®Google Scholar
• Anthonisen NR, Connett JE, Kiley JP, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA 1994;272:1497-505
   Google Scholar
• Anthonisen NR, Skeans MA, Wise RA, et al. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med 2005;142:233-9
   PubMed Web of Science ®Google Scholar
• Celli BR, MacNee W, ATS/ERS committee members. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004;23:932-46
   PubMed Web of Science ®Google Scholar
• Okuyemi KS, Nollen NL, Ahluwalia JS. Interventions to facilitate smoking cessation. Am Fam Physician 2006;74:262-71
   PubMed Web of Science ®Google Scholar
• Willemse BW, ten Hacken NH, Rutgers B, et al. Effect of 1-year smoking cessation on airway inflammation in COPD and asymptomatic smokers. Eur Respir J 2005;26:835-45
   PubMed Web of Science ®Google Scholar
• Lapperre TS, Postma DS, Gosman MM, et al. Relation between duration of smoking cessation and bronchial inflammation in COPD. Thorax 2006;61:115-21
   PubMed Web of Science ®Google Scholar
• Gamble E, Grootendorst DC, Hattotuwa K, et al. Airway mucosal inflammation in COPD is similar in smokers and ex-smokers: a pooled analysis. Eur Respir J 2007;30:467-71
   PubMed Web of Science ®Google Scholar
• Willemse BW, ten Hacken NH, Rutgers B, et al. Smoking cessation improves both direct and indirect airway hyperresponsiveness in COPD. Eur Respir J 2004;24:391-6
   PubMed Web of Science ®Google Scholar
• Garrod R, Ansley P, Canavan J, et al. Exercise and the inflammatory response in chronic obstructive pulmonary disease (COPD) – does training confer anti-inflammatory properties in COPD? Med Hypotheses 2007;68:291-8
   PubMed Web of Science ®Google Scholar
• Appleton S, Poole P, Smith B, et al. Long-acting beta2-agonists for poorly reversible chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2006;3:CD001104
   Google Scholar
• Sin DD, McAlister FA, Man SF, et al. Contemporary management of chronic obstructive pulmonary disease: scientific review. JAMA 2003;290:2301-12
   PubMed Web of Science ®Google Scholar
• Barr RG, Bourbeau J, Camargo CA, et al. Tiotropium for stable chronic obstructive pulmonary disease: A meta-analysis. Thorax 2006;61:854-62
   PubMed Web of Science ®Google Scholar
• Soriano JB, Sin DD, Zhang X, et al. A pooled analysis of FEV1 decline in COPD patients randomized to inhaled corticosteroids or placebo. Chest 2007;131:682-9
   PubMed Web of Science ®Google Scholar
• Alsaeedi A, Sin DD, McAlister FA. The effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review of randomized placebo-controlled trials. Am J Med 2002;113:59-65
   PubMed Web of Science ®Google Scholar
• Sin DD, Wu L, Anderson JA, et al. Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease. Thorax 2005;60:992-7
   PubMed Web of Science ®Google Scholar
• COMBIVENT Inhalation Aerosol Study GroupIn chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. An 85-day multicenter trial. Chest 1994;105:1411-19
   PubMed Web of Science ®Google Scholar
• Gross N, Tashkin D, Miller R, et al. Inhalation by nebulization of albuterol-ipratropium combination (Dey combination) is superior to either agent alone in the treatment of chronic obstructive pulmonary disease. Dey Combination Solution Study Group. Respiration 1998;65:354-62
   Google Scholar
• Baloira Villar A, Vilarino Pombo C. Bronchodilator efficacy of combined salmeterol and tiotropium in patients with chronic obstructive pulmonary disease. Arch Bronconeumol 2005;41:130-4
   PubMed Web of Science ®Google Scholar
• Aaron SD, Vandemheen KL, Fergusson D, et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 2007;146:545-55
   PubMed Web of Science ®Google Scholar
• Nannini LJ, Cates CJ, Lasserson TJ, et al. Combined corticosteroid and long-acting beta-agonist in one inhaler versus placebo for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2007;4:CD003794
   Google Scholar
• Nannini LJ, Cates CJ, Lasserson TJ, et al. Combined corticosteroid and long-acting beta-agonist in one inhaler versus long-acting beta-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2007;4:CD006829
   PubMed Web of Science ®Google Scholar
• Nannini LJ, Cates CJ, Lasserson TJ, et al. Combined corticosteroid and long-acting beta-agonist in one inhaler versus inhaled steroids for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2007;4:CD006826
   PubMed Web of Science ®Google Scholar
• Calverley P, Pauwels R, Vestbo J, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003;361:449-56
   PubMed Web of Science ®Google Scholar
• Calverley PM, Boonsawat W, Cseke Z, et al. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J 2003;22:912-19
   PubMed Web of Science ®Google Scholar
• Szafranski W, Cukier A, Ramirez A, et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 2003;21:74-81
   PubMed Web of Science ®Google Scholar
• Celli B, Thomas NE, Anderson JA, et al. Effect of pharmacotherapy on rate of decline of lung function in COPD: results from the TORCH study. Am J Respir Crit Care Med 2008;178:332-8
   PubMed Web of Science ®Google Scholar
• Keddissi JI, Younis WG, Chbeir EA, et al. The use of statins and lung function in current and former smokers. Chest 2007;132:1764-71
   PubMed Web of Science ®Google Scholar
• Barnes NC, Qiu YS, Pavord ID, et al. Antiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease. Am J Respir Crit Care Med 2006;173:736-43
   PubMed Web of Science ®Google Scholar
• Bourbeau J, Christodoulopoulos P, Maltais F, et al. Effect of salmeterol/fluticasone propionate on airway inflammation in COPD: a randomized controlled trial. Thorax 2007;62:938-43
   PubMed Web of Science ®Google Scholar
• Sin DD, Lacy P, York E, et al. Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004;170:760-5
   PubMed Web of Science ®Google Scholar
• Adcock IM, Maneechotesuwan K, Usmani O. Molecular interactions between glucocorticoids and long-acting beta2-agonists. J Allergy Clin Immunol 2002;110:S261-8
   PubMedGoogle Scholar
• Sin DD, Man SF. Corticosteroids and adrenoceptor agonists: the compliments for combination therapy in chronic airways diseases. Eur J Pharmacol 2006;533:28-35
   PubMed Web of Science ®Google Scholar
• van der Vaart H, Koëter GH, Postma DS, et al. First study of infliximab treatment in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005;172:465-69
   PubMed Web of Science ®Google Scholar
• Rennard SI, Fogarty C, Kelsen S, et al. The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007;175:926-34
   PubMed Web of Science ®Google Scholar